GPT and Hyperglycemia: Two inclisiran studies included severe and fatal adverse events such as liver injury (defined as an increase in AST or ALT three above the limit of normal or bilirubin two above the limit of normal) and kidney adverse events (defined as increasing creatinine > 2 mg/dl), thrombocytopenia and hyperglycemia [24, 26].